ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

详细信息    查看全文

• 作者：Lifeng Wang (1)
  Jia Wei (1)
  Xiaoping Qian (1)
  Haitao Yin (1)
  Yang Zhao (2)
  Lixia Yu (1)
  Tingting Wang (1)
  Baorui Liu (1)
  
• 刊名：BMC Cancer
• 出版年：2008
• 出版时间：December 2008
• 年：2008
• 卷：8
• 期：1
• 全文大小：812KB
• 参考文献：1. Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, Santarpia M, Moran T, Catot S, Etxaniz O: Application of genomics in NSCLC. / Lung Cancer 2005, (Suppl 2) : S33鈥?0.
  2. Lee W, Lockhart AC, Kim RB, Rothenberg ML: Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. / Oncologist 2005, 10: 104鈥?1. CrossRef
  3. Mehlen P, Puisieux A: Metastasis: a question of life or death. / Nature Rev Cancer 2006, 6 (6) : 449鈥?8. CrossRef
  4. Christofori G: New signals from the invasive front. / Nature 2006, 441: 444鈥?0. CrossRef
  5. Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B: Expression of xeroderma pigmentosum a protein predicts improved outcome in metastatic ovarian carcinoma. / Cancer 2005, 103 (11) : 2313鈥?9. CrossRef
  6. Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. / Clin Cancer Res 2000, 6: 4797鈥?802.
  7. Westra JL, Hollema H, Schaapveld M, Platteel I, Oien KA, Keith WN, Mauritz R, Peters GJ, Buys CH, Hofstra RM, Plukker JT: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. / Ann Oncology 2005, 16 (10) : 1646鈥?653. CrossRef
  8. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groschen S, Cohen H, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumour response and overall survival. / J Clin Oncol 1996, 14: 176鈥?2.
  9. Vogel U, Dybdahl M, Frentz G, Nexo BA: DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. / Mutat Res 2000, 461: 197鈥?10.
  10. Kwon HC, Roh M, Oh S, Kim SH, Kim M, Kim JS, Kim HJ: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. / Ann Oncol 2007, 18: 504鈥?. CrossRef
  11. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IALT Bio Investigators: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. / N Eng J Med 2006, 335 (10) : 983鈥?91. CrossRef
  12. Park DJ, Lenz HJ: Determination of chemosensitivity in gastric cancer. / Curr Opin Pharmacol 2006, 6: 337鈥?44. CrossRef
  13. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. / Cancer Res 2003, 63: 6221鈥?.
  14. Rosell R, Cecere F, Santarpia M, Reguart N, Taron M: Predicting the outcome of chemotherapy for lung cancer. / Curr Opin Pharmacol 2006, 6: 323鈥?31. CrossRef
  15. Mullan PB, Quinn JE, Harkin DP: The role of BRCA1 in transcriptional regulation and cell cycle control. / Oncogene 2006, 25: 5854鈥?3. CrossRef
  16. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP: The role of BRCA1 in the cellular response to chemotherapy. / J Nat Cancer Inst 2004, 96: 1659鈥?8. CrossRef
  17. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. / Hum Mol Genet 2004, 13: 2443鈥?. CrossRef
  18. Kennedy RD, Quinn JE, Johnston PG, Harkin DP: BRCA1: mechanisms of inactivation and implications for management of patients. / Lancet 2002, 360: 1007鈥?4. CrossRef
  19. Kurebayashi J, Yamamoto Y, Kurosumi M, Okubo S, Nomura T, Tanaka K, Sonoo H: Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. / Anticancer Res 2006, 26: 695鈥?02.
  20. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. / Cancer Res 1995, 55: 5276鈥?2.
  21. Ugurel S, Schadendorf D, Pfohler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U, Dermatologic Cooperative Oncology Group: In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the dermatologic cooperative oncology group. / Clin Cancer Res 2006, 12: 5454鈥?3. CrossRef
  22. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, amont A, Gulliford T, Hurren J, Yiangou C, Cree IA: Cancer cell adaptation to chemotherapy. / BMC Cancer 2005, 5: 78. CrossRef
  23. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E: Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human cancer cells. / J Bio Chem 1998, 273 (36) : 23419鈥?3425. CrossRef
  24. Konstantinovsky S, Nielsen S, Vyberg M, Kvalheim G, Nesland JM, Reich R, Davidson B: Angiogenic molecule expression is downregulated in effusions from breast cancer patients. / Breast Cancer Res Treat 2005, 94: 71鈥?0. CrossRef
  25. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K: EGFR mutation status in tumor-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. / Br J Cancer 2006, 95: 1390鈥?. CrossRef
  26. Neragi-Miandoab S: Malignant pleural effusion. Current and evolving approaches for its diagnosis and management. / Lung cancer 2006, 54: 1鈥?. CrossRef
  27. Schmidt M, Bremer E, Hasenclever D, Victor A, Gehrmann M, Steiner E, Schiffer IB, Gebhardt S, Lehr HA, Mahlke M, Hermes M, Mustea A, Tanner B, Koelbl H, Pilch H, Hengstler JG: Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. / Br J Cancer 2007, 96: 241鈥?. CrossRef
  28. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/97/prepub
  
• 作者单位：Lifeng Wang (1)
  Jia Wei (1)
  Xiaoping Qian (1)
  Haitao Yin (1)
  Yang Zhao (2)
  Lixia Yu (1)
  Tingting Wang (1)
  Baorui Liu (1)
  
  1. Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China
  2. Department of Epidemiology and Biostatistics, Epidemiology and Biostatistics Graduate Program, Data Analysis Center, School of Public Health, Nanjing Medical University, 210019, Nanjing, China
  
• ISSN：1471-2407

文摘

Background One of the major challenges in currently chemotherapeutic theme is lacking effective biomarkers for drug response and sensitivity. Our current study focus on two promising biomarkers, ERCC1 (excision repair cross-complementing group 1) and BRCA1 (breast cancer susceptibility gene 1). To investigate their potential role in serving as biomarkers for drug sensitivity in cancer patients with metastases, we statistically measure the mRNA expression level of ERCC1 and BRCA1 in tumor cells isolated from malignant effusions and correlate them with cisplatin and/or docetaxel chemosensitivity. Methods Real-time quantitative PCR is used to analysis related genes expression in forty-six malignant effusions prospectively collected from non-small cell lung cancer (NSCLC), gastric and gynecology cancer patients. Viable tumor cells obtained from malignant effusions are tested for their sensitivity to cisplatin and docetaxel using ATP-TCA assay. Results ERCC1 expression level is negatively correlated with the sensitivity to cisplatin in NSCLC patients (P = 0.001). In NSCLC and gastric group, BRCA1 expression level is negatively correlated with the sensitivity to cisplatin (NSCLC: P = 0.014; gastric: P = 0.002) while positively correlated with sensitivity to docetaxel (NSCLC: P = 0.008; gastric: P = 0.032). A significant interaction is found between ERCC1 and BRCA1 mRNA expressions on sensitivity to cisplatin (P = 0.010, n = 45). Conclusion Our results demonstrate that ERCC1 and BRCA1 mRNA expression levels are correlated with in vitro chemosensitivity to cisplatin and/or docetaxel in malignant effusions of NSCLC and gastric cancer patients. And combination of ERCC1 and BRCA1 may have a better role on predicting the sensitivity to cisplatin than the single one is considered.